O35 B-cell depletion and response in a randomized, controlled trial of obinutuzumab for proliferative lupus nephritis. (23rd March 2020)
- Record Type:
- Journal Article
- Title:
- O35 B-cell depletion and response in a randomized, controlled trial of obinutuzumab for proliferative lupus nephritis. (23rd March 2020)
- Main Title:
- O35 B-cell depletion and response in a randomized, controlled trial of obinutuzumab for proliferative lupus nephritis
- Authors:
- Furie, Richard
Cascino, Matthew D
Garg, Jay P
Aroca, Gustavo
Alvarez, Analía
Fragoso-Loyo, Hilda
Santillán, Elizabeth Zuta
Malvar, Ana
Brunetta, Paul G
Schindler, Thomas
Looney, Cary Michael Donna
Hassan, Imran
Rovin, Brad H - Abstract:
- Abstract : Background: Previous analyses identified associations between the degree of B-cell depletion and response in lupus nephritis (LN). NOBILITY tested whether enhanced B-cell depletion with the type II anti-CD20 mAb obinutuzumab could improve responses in LN. Methods: 126 patients with active Class III/IV LN were randomized to obinutuzumab or placebo infusions in combination with mycophenolate and corticosteroids. Peripheral B-cells were measured using a flow cytometry method with a lower limit of 0.441 cells/μL. Sustained depletion was assessed by flow cytometry measurements at weeks 24 and 52. Results: Obinutuzumab was associated with increased CRR (40% vs. 18%, P=0.007) and ORR (51% vs. 29%, P =0.015) at week 76. Obinutuzumab resulted in rapid and complete depletion of peripheral B-cells, memory and naïve B-cell subsets, and plasmablasts, with 89% of obinutuzumab patients depleted to <0.441 CD19+ cells/μL at week 4. Among obinutuzumab patients, sustained B-cell depletion was associated with greater renal response at week 76 (table 1 ), although patients who achieved sustained depletion also had lower baseline proteinuria and serum creatinine. Conclusions: Obinutuzumab, a type II anti-CD20 mAb, induced rapid and complete depletion of peripheral B-cells and B-cell subsets. Similar to previous reports, sustained B-cell depletion was associated with increased renal response. Further evaluation is ongoing to understand the factors associated with achievement ofAbstract : Background: Previous analyses identified associations between the degree of B-cell depletion and response in lupus nephritis (LN). NOBILITY tested whether enhanced B-cell depletion with the type II anti-CD20 mAb obinutuzumab could improve responses in LN. Methods: 126 patients with active Class III/IV LN were randomized to obinutuzumab or placebo infusions in combination with mycophenolate and corticosteroids. Peripheral B-cells were measured using a flow cytometry method with a lower limit of 0.441 cells/μL. Sustained depletion was assessed by flow cytometry measurements at weeks 24 and 52. Results: Obinutuzumab was associated with increased CRR (40% vs. 18%, P=0.007) and ORR (51% vs. 29%, P =0.015) at week 76. Obinutuzumab resulted in rapid and complete depletion of peripheral B-cells, memory and naïve B-cell subsets, and plasmablasts, with 89% of obinutuzumab patients depleted to <0.441 CD19+ cells/μL at week 4. Among obinutuzumab patients, sustained B-cell depletion was associated with greater renal response at week 76 (table 1 ), although patients who achieved sustained depletion also had lower baseline proteinuria and serum creatinine. Conclusions: Obinutuzumab, a type II anti-CD20 mAb, induced rapid and complete depletion of peripheral B-cells and B-cell subsets. Similar to previous reports, sustained B-cell depletion was associated with increased renal response. Further evaluation is ongoing to understand the factors associated with achievement of sustained B-cell depletion and renal response. Acknowledgements: This study was funded by F. Hoffmann-La Roche. … (more)
- Is Part Of:
- Lupus science & medicine. Volume 7(2020)Supplement 1
- Journal:
- Lupus science & medicine
- Issue:
- Volume 7(2020)Supplement 1
- Issue Display:
- Volume 7, Issue 1 (2020)
- Year:
- 2020
- Volume:
- 7
- Issue:
- 1
- Issue Sort Value:
- 2020-0007-0001-0000
- Page Start:
- A27
- Page End:
- A28
- Publication Date:
- 2020-03-23
- Subjects:
- Systemic lupus erythematosus -- Periodicals
616.772005 - Journal URLs:
- http://www.bmj.com/archive ↗
http://lupus.bmj.com/ ↗ - DOI:
- 10.1136/lupus-2020-eurolupus.46 ↗
- Languages:
- English
- ISSNs:
- 2398-8851
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 19741.xml